[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
[2] |
Rusthoven CG, Rabinovitch RA, Jones BL, et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis[J]. Ann Oncol, 2016, 27(5): 818-827.
|
[3] |
Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: a 25-year study[J]. Asian Pac J Cancer Prev, 2019, 20(7): 2015-2020.
|
[4] |
Doval DC, Dutta K, Batra U, et al. Neoadjuvant chemotherapy in breast cancer: review of literature[J]. J Indian Med Assoc, 2013, 111(9): 629-631.
|
[5] |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
|
[6] |
Colomer R, Saura C, Sánchez-Rovira P, et al. Neoadjuvant management of early breast cancer: a clinical and investigational position statement[J]. Oncologist, 2019, 24(5): 603-611.
|
[7] |
Kim HY, Kim TH, Yoon HK, et al. The role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting neoadjuvant chemotherapy response in breast cancer[J]. J Breast Cancer, 2019, 22(3): 425-438.
|
[8] |
Graziano V, Grassadonia A, Iezzi L, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients[J]. Breast, 2019, 44: 33-38.
|
[9] |
Chen L, Kong X, Wang Z, et al. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy[J]. J Cell Mol Med, 2020, 24(5): 2993-3021.
|
[10] |
Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival[J]. Breast (Edinburgh, Scotland), 2003, 12(5): 320-327.
|
[11] |
Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update[J]. J Clin Oncol, 2020, 38(12): 1346-1366.
|
[12] |
《乳腺癌HER2检测指南》编写组. 乳腺癌HER2检测指南(2019版)[J]. 中华病理学杂志,2019, 48(3): 169-175.
|
[13] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志,2021, 31(10): 954-1040.
|
[14] |
Danforth DN. The role of chronic inflammation in the development of breast cancer[J]. Cancers (Basel), 2021, 13(15): 3918.
|
[15] |
Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment[J]. Nat Rev Immunol, 2007, 7(1): 41-51.
|
[16] |
Liu S, Lachapelle J, Leung S, et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer[J]. Breast Cancer Res, 2012, 14(2): R48.
|
[17] |
Rangan R, Kanetkar SR, Bhosale SJ, et al. Evaluation and comparison of intratumoural and intrastromal infiltrating lymphocytes with clinicopathological features in breast carcinoma patients who have received neoadjuvant chemotherapy-A cross-sectional study[J]. Ann Med Surg (Lond), 2022, 80: 104 308.
|
[18] |
Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic[J]. Nat Rev Clin Oncol, 2016, 13(4): 228-241.
|
[19] |
Guo Y, Cui W, Pei Y, et al. Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-β signaling pathway[J]. Gynecol Oncol, 2019, 153(3): 639-650.
|
[20] |
Liu S, Fang J, Jiao D, et al. Elevated platelet count predicts poor prognosis in breast cancer patients with supraclavicular lymph node metastasis[J]. Cancer Manag Res, 2020, 12: 6069-6075.
|
[21] |
Jalali A, Miresse D, Fahey MR, et al. Peripheral blood cell ratios as prognostic indicators in a neoadjuvant chemotherapy-treated breast cancer cohort[J]. Curr Oncol, 2022, 29(10): 7512-7523.
|
[22] |
Grassadonia A, Graziano V, Iezzi L, et al. Prognostic relevance of neutrophil to lymphocyte ratio (NLR) in luminal breast cancer: a retrospective analysis in the neoadjuvant setting[J]. Cells, 2021, 10(7): 1685.
|
[23] |
Li X, Tan Q, Li H, et al. Predictive value of pretreatment peripheral neutrophil-to-lymphocyte ratio for response to neoadjuvant chemotherapy and breast cancer prognosis[J]. Cancer Manag Res, 2021, 13: 5889-5898.
|
[24] |
Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(23): 6212-6222.
|
[25] |
Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic in dicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Cancer Manag Res, 2017, 9: 849-867.
|
[26] |
Yang J, Guo X, Wang M, et al. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS[J]. Sci Rep, 2017, 7(1): 17 166.
|
[27] |
Wang P, Yue W, Li W, et al. Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer[J]. Cancer Manag Res, 2019, 11: 813-819.
|
[28] |
Liu J, Shi Z, Bai Y, et al. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer[J]. Cancer Manag Res, 2019, 11: 4471-4480.
|
[29] |
Jiang L, Fang J, Ding J. High systemic immune-inflammation index predicts poor survival in patients with human epidermal growth factor receptor-2 positive breast cancer receiving adjuvant trastuzumab[J]. Cancer Manag Res, 2020, 12: 475-484.
|
[30] |
Yu Y, Wu S, Xing H, et al. Development and validation of a novel model for predicting prognosis of non-pCR patients after neoadjuvant therapy for breast cancer[J]. Front Oncol, 2021, 11: 675 533.
|
[31] |
Boér K, Kahán Z, Landherr L, et al. Pathologic complete response rates after neoadjuvant pertuzumab and trastuzumab with chemotherapy in early stage HER2-positive breast cancer - increasing rates of breast conserving surgery: a real-world experience[J]. Pathol Oncol Res, 2021, 27: 1 609 785.
|
[32] |
Guan D, Jie Q, Wu Y, et al. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China[J]. World J Surg Oncol, 2022, 20(1): 326.
|